+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07602166

Study of 2-HOBA to Reduce Salt Sensitivity of Blood Pressure and Immune Cell Activation in Adults with Hypertension

Led by Vanderbilt University Medical Center · Updated on 2026-11-04

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating salt sensitivity of blood pressure SSBP, a condition linked to hypertension and increased risks of heart attack, stroke, heart failure, and kidney disease. This phase 2 clinical trial explores how immune cells contribute to SSBP, particularly focusing on the role of isolevuglandins IsoLGs produced by myeloid cells. The study evaluates the potential of 2-hydroxybenzylamine 2-HOBA, an IsoLG scavenger, to reduce endothelial dysfunction and immune cell activation that may perpetuate salt sensitivity. Participants with confirmed salt-sensitive blood pressure will undergo a 12-week, randomized, double-blind, placebo-controlled, 2x2 crossover study. They will receive either 2-HOBA 500 mg three times daily or placebo for 4 weeks, followed by a 4-week washout, then switch to the other treatment for 4 weeks. Salt loading and depletion protocols, including controlled diets and saline infusions, will be used to measure blood pressure responses and immune activity at specific weeks. Throughout the study, participants will have ambulatory blood pressure monitoring, blood and urine collections for laboratory analyses, and assessments of immune cell activation and vascular function. Procedures include flow-mediated vasodilation FMD ultrasound and endothelial cell harvesting. Researchers will measure changes in systolic blood pressure, oxidative stress markers, inflammatory cytokines, and endothelial health. The trial spans from week 0 to 12, with evaluations at weeks 0, 4, 8, and 12.

CONDITIONS

Brief Title

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

Research Team

A

Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A.

C

Cindy Mambungu, LPN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here